Apigamon contains Nalidixic Acid. Apigamon uses:
Nalidixic acid is indicated in -
- Urinary tract infections caused by susceptible Gram-negative microorganisms, including the majority of Proteus strains, Klebsiella, Enterobacter spp. and E. coli.
- Gastrointestinal infections caused by Salmonella and Shigella.
|Therapeutic Class:||Anti-diarrhoeal Antimicrobial drugs, Other Anti-protozoals, Systemic Urinary Anti- infective|
|Manufacturer:||Apollo Pharmaceutical Laboratories Ltd|
|Last Updated:||November 19, 2020 at 6:15 pm|
Nalidixic acid is a synthetic narrow spectrum antibacterial. It is bacteriostatic or bactericidal depending on the concentration. Nalidixic acid appears to act by inhibiting bacterial DNA synthesis, possibly by interfering with DNA polymerization. It is rapidly and completely absorbed from the G.I. Tract. Parent drug and active metabolites are distributed to most tissues specially to the kidney and to the urine.
Apigamon contains Nalidixic Acid 500 mg. Apigamon Dosage:
- Initial: Oral 1 gm every 6 hours for 7 days reducing to 500 mg every 6 hours.
Infants and children 3 month of age and over:
- Initial: Oral 13.75 mg/kg body weight every six hours for one or two weeks.
- Maintenance: Oral 8.25 mg/kg body weight every six hours or as prescribed by the physician.
Should be taken with food.
Gastro-intestinal disturbances including nausea, vomiting, diarrhoea, haemolysis in G6PD deficiency, allergic reaction including urticaria, rashes, fever, arthralgia, eosinophilia, also myalgia, muscle weakness, phototoxicity, jaundice, visual disturbances and convulsions.
General: Should be used with caution in liver disease, epilepsy or severe cerebral arteriosclerosis patients. Periodic blood counts and renal and liver function tests should be performed if treatment is continued for more than 2 weeks. If bacterial resistance emerges, rapid change of drug should be made.
Children: Should not be used to infants less than 3 months of age.
Concomitant use of Nalidixic acid with melphalan there have been reports of death froms severe blood containing diarrhoea caused by hemorrhagic ulcerative colitis. Probenecids inhibits tubular secretion of nalidixic acid and may therefore elevate serum concentration, possibly enhancing toxicity. Chlorpromazine and Perphenazine have been shown to potentiate the effect of Apigamon in vitro.
Pregnancy Lactation use
Pregnancy: There is the possibility that it may cause cartilage damage and as it is a DNA-gyrase inhibitor there is a possibility of causing DNA damage too. Nalidixic acid is excreted in breast milk and there is a report of hemolytic anaemia in a breast feed child of an azotemic mother.
Apigamon is contraindicated to known hypersensitivity to Nalidixic acid, history of convulsive disorders and patients with porphyria. Should be used with caution in patients with liver and renal disease. Also in glucose 6 - phosphate dehydrogenase deficiency.
Renal Impairment: Reduced doses should be considered.
Hepatic Impairment: Reduced doses should be considered.
Symptoms: Toxic psychosis, convulsions, increased intracranial pressure, metabolic acidosis, vomiting, nausea, lethargy.
Management: Increase fluid admin; supportive measures. Anticonvulsants may be used in severe cases.
Interaction with other Medicine
Store at room temperature, up to 25° C
Apigamon Tablet price in Bangladesh 5.53